![]() |
Name |
Seco-4-epi-7-epi-brefeldin A methyl ester
|
Molecular Formula | C17H28O5 | |
IUPAC Name* |
methyl4-hydroxy-4-[4-hydroxy-2-(6-hydroxyhept-1-enyl)cyclopentyl]but-2-enoate
|
|
SMILES |
COC(=O)C=CC(O)C1CC(O)CC1C=CCCCC(C)O
|
|
InChI |
InChI=1S/C17H28O5/c1-12(18)6-4-3-5-7-13-10-14(19)11-15(13)16(20)8-9-17(21)22-2/h5,7-9,12-16,18-20H,3-4,6,10-11H2,1-2H3/b7-5+,9-8+/t12-,13+,14+,15+,16-/m0/s1
|
|
InChIKey |
XIEAZFBKNHWJIU-KSGHCOCSSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 312.41 | ALogp: | 1.6 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 22 | QED Weighted: | 0.277 |
Caco-2 Permeability: | -4.577 | MDCK Permeability: | 0.00033154 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.039 |
Human Intestinal Absorption (HIA): | 0.286 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.961 |
Blood-Brain-Barrier Penetration (BBB): | 0.775 | Plasma Protein Binding (PPB): | 33.87% |
Volume Distribution (VD): | 1.163 | Fu: | 54.94% |
CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.556 |
CYP2C19-inhibitor: | 0.039 | CYP2C19-substrate: | 0.782 |
CYP2C9-inhibitor: | 0.017 | CYP2C9-substrate: | 0.602 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.229 |
CYP3A4-inhibitor: | 0.172 | CYP3A4-substrate: | 0.308 |
Clearance (CL): | 11.533 | Half-life (T1/2): | 0.913 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.241 |
Drug-inuced Liver Injury (DILI): | 0.037 | AMES Toxicity: | 0.016 |
Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.723 |
Skin Sensitization: | 0.134 | Carcinogencity: | 0.543 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.067 |
Respiratory Toxicity: | 0.033 |